Upload
metapresents
View
833
Download
0
Tags:
Embed Size (px)
DESCRIPTION
This presentation looks at the priorities for the work of the Medicines Transparency Alliance (MeTA) Jordan Council. It was made by Dr Lama Al Homoud at the launch of MeTA Jordan in May 2009
Citation preview
Pharmacist Lama Al.HomoudDirector of Clinical Pharmacy Directorate / MOH
MeTA Committee 1: Encouraging best practice & Improve Rational Use of Medicines
1
Committee Members
Dr Taher Abu-ElSamen, HHC, SG Dr Laila Jarrar, JFDA, Drug Director Dr Wafa Nsour, RMS , Pharmacy & Drug Director Dr Khawla Abu Hamour, JUH ,Pharmacy Director Dr Sana Naffa, WHO Dr Lama Al. Homoud, MOH, Clinical Pharmacy Director
2
Background
Clinical guidelines and treatment protocols are two of the major ways to ensure that the health care treatment options provided to populations are the best and most appropriate that the country could afford
3
Background
Standardization of protocols in a selected disease area by using the Rational Drug List
Increasing the acceptability/impact of RDL and reducing variation/inequity in current practices
4
1.Encouraging Best Practice / Improve Rational Use of Medicine
2.Evidence Based Decision Making for the (RDL)
3.Capacity Building in Civil Society
Priority Areas in Jordan’s MeTA Workplan
5
Scope of Work
Improve rational use of medicines: Consolidation and implementation of Standard
Treatment Guidelines Working with physicians and pharmacists to improve
prescribing behavior through training &continuing professional educational programs
Promoting the use of standard treatment guidelines
6
Improve rational use of medicines
Strategies adopted by MeTA / Jordan: Strategy I: Assessment and gap analysis Strategy II: Development and Implementation
plan for the Standard Treatment Guidelines Strategy III: Evaluation of a pilot area and
Multi-Sectoral Dissemination
7
Strategy I: Assessment and gap analysis
Activities: Assessing the current guidelines used in different
sectors Performing gap analysis of the current situation;
what standards are used, what services are covered, are these standards implemented?
8
Strategy I:Assessment and gap analysis
Activities: Reviewing the perception and use of the existing
treatment guidelines Knowledge, Attitude and Practice Study (KAP study)
Defining the committee targets and future steps in developing, adopting or consolidating the standards
Identifying the scope, purpose and use of these guidelines
9
Strategy II: Development and Implementation plan for the STG
Activities:• Finalizing and approving STG• Disseminating the guidelines in the pilot area through
orientation and training sessions • Involving the Hospital Pharmacy and Therapeutic
committees to activate their role in the implementation and monitoring processes
10
Strategy III:Evaluation of a pilot area & Multi-Sectoral dissemination
Activities:
Evaluate the compliance with STG in the pilot areaPrepare an advocacy tool using evidence and figures on cost containment and efficiencies in medicine expenditureUse Multi-Sectoral approach towards a national program to promote rational use of medicines
11
Work plan Sub-activities
1- Gap Analysis and situation analysis for the availability and use of STG in health facilities in Jordan:
a. Formulate a technical work group from public health institutions (MOH, JFDA, RMS and JUH)
b. Design a tool for collecting data regarding availability of the STG and the compliance to these standards
c. Conducting a comparative study with international STG
d. Analysis of findings, conclusion and recommendations
Work plan Sub-activities
2- Three regional workshops to build consensus and get feedback from all parties on the final STG draft
3- Finalizing and approving STG
4- produce copies of the STG with job aids, posters and other materials to be used in public health facilities
13
Performance Progress and Evaluation
. Gap analysis and availability of existing guidelines Strategy developed and disseminated Finalization and approval of the STG Dissemination of guidelines in the pilot area Evaluate the compliance with standards in the pilot
area Continuing professional education programs
14
Means of VerificationPerformance Indicators
Gap analysis and assessment report finalized Workshop conducted Pilot conducted Report to be delivered CPE Programs done
15
Expected outcomes
The establishment of a multi-stakeholder approach that will be working towards increasing transparency focusing on the regulations, selection, procurement, and distribution of medicines
Strengthening governance Maximizing cost benefit utilization of medicines by
healthcare professionals
16
National Institute for Clinical Excellence (NICE)
An organization that is responsible for providing national guidance on promoting good health
A training workshop was conducted by NICE on Using Health Technology Assessment to inform decision-making in healthcare March 2009
Another workshop is planned for mid June 2009 to start with a pilot disease oriented STG (Hypertension)
17
National Institute for Clinical Excellence (NICE)
NICE involvement can be of benefit in two areas of strategic importance for improving the transparency of the way our healthcare system functions:
A) Best practice (STG), including harmonization of existing ones and methods and processes of adapting or developing new ones in high burden of disease areas
B) RDL including the methods and processes of making and listing and delisting decisions, considerations of cost effectiveness and of affordability
18
19